Alfred Hanswillemenke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alfred Hanswillemenke has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Thorsten Stafforst
Interfaculty Institute of Biochemistry, University of Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany
3 shared publications Carolin Fruhner
Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany
2 shared publicationsAdrian Brun
Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany
1 shared publication- Anna Sofia Imrich
Interfaculty Institute of Biochemistry, University of Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany
1 shared publication - Boris Macek
Proteome Center Tübingen, University of Tübingen, Tübingen, Germany
1 shared publication - Daniel Tobias Hofacker
Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany
1 shared publication
Latest Publications
- Open Access
Light-Controlled Assembly and Disassembly of Covalent RNA–Protein Conjugates to Control RNA Base Editing
Self-labeling enzymes, like SNAP-, CLIP- and Halo-tag have found wide application in biology, biochemistry, materials science and bioengineering. For example, they have been applied with high versatility to rewrite genetic information inside the living cell by providing rationally programmable RNA-targeting strategies of protein-based effectors. Such approaches benefit from the engineering capability of the small molecule-based self-labeling moieties. Here, we further engineered that approach to control RNA-targeting by light. Specifically, we combined two orthogonal self-labeling enzymes for the recruitment of two distinct fusion proteins to a target RNA inside the living cell and achieved concurrent assembly and disassembly of distinct guide RNA–protein conjugates. We applied this to control RNA base editing and achieved a photo-induced swap of two distinct editing events. Overall, this work describes new ways for tool development, RNA imaging, and transcript engineering.
Open AccessLight-Controlled Assembly and Disassembly of Covalent RNA–Protein Conjugates to Control RNA Base Editing
Self-labeling enzymes, like SNAP-, CLIP- and Halo-tag have found wide application in biology, biochemistry, materials science and bioengineering. For example, they have been applied with high versatility to rewrite genetic information inside the living cell by providing rationally programmable RNA-targeting strategies of protein-based effectors. Such approaches benefit from the engineering capability of the small molecule-based self-labeling moieties. Here, we further engineered that approach to control RNA-targeting by light. Specifically, we combined two orthogonal self-labeling enzymes for the recruitment of two distinct fusion proteins to a target RNA inside the living cell and achieved concurrent assembly and disassembly of distinct guide RNA–protein conjugates. We applied this to control RNA base editing and achieved a photo-induced swap of two distinct editing events. Overall, this work describes new ways for tool development, RNA imaging, and transcript engineering.
- Open Access
- 5 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
An improved SNAP-ADAR tool enables efficient RNA base editing to interfere with post-translational protein modification
RNA base editing relies on the introduction of adenosine-to-inosine changes into target RNAs in a highly programmable manner in order to repair disease-causing mutations. Here, we propose that RNA base editing could be broadly applied to perturb protein function by removal of regulatory phosphorylation and acetylation sites. We demonstrate the feasibility on more than 70 sites in various signaling proteins and identify key determinants for high editing efficiency and potent down-stream effects. For the JAK/STAT pathway, we demonstrate both, negative and positive regulation. To achieve high editing efficiency over a broad codon scope, we applied an improved version of the SNAP-ADAR tool. The transient nature of RNA base editing enables the comparably fast (hours to days), dose-dependent (thus partial) and reversible manipulation of regulatory sites, which is a key advantage over DNA (base) editing approaches. In summary, PTM interference might become a valuable field of application of RNA base editing.
- 5 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessAn improved SNAP-ADAR tool enables efficient RNA base editing to interfere with post-translational protein modification
RNA base editing relies on the introduction of adenosine-to-inosine changes into target RNAs in a highly programmable manner in order to repair disease-causing mutations. Here, we propose that RNA base editing could be broadly applied to perturb protein function by removal of regulatory phosphorylation and acetylation sites. We demonstrate the feasibility on more than 70 sites in various signaling proteins and identify key determinants for high editing efficiency and potent down-stream effects. For the JAK/STAT pathway, we demonstrate both, negative and positive regulation. To achieve high editing efficiency over a broad codon scope, we applied an improved version of the SNAP-ADAR tool. The transient nature of RNA base editing enables the comparably fast (hours to days), dose-dependent (thus partial) and reversible manipulation of regulatory sites, which is a key advantage over DNA (base) editing approaches. In summary, PTM interference might become a valuable field of application of RNA base editing.
- Open Access
- 17 January 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (5) , 555-565
Profiling the interactome of oligonucleotide drugs by proximity biotinylation
Drug-ID is a novel method applying proximity biotinylation to identify drug–protein interactions inside living cells. The covalent conjugation of a drug with a biotin ligase enables targeted biotinylation and identification of the drug-bound proteome. We established Drug-ID for two small-molecule drugs, JQ1 and SAHA, and applied it for RNaseH-recruiting antisense oligonucleotides (ASOs). Drug-ID profiles the drug–protein interactome de novo under native conditions, directly inside living cells and at pharmacologically effective drug concentrations. It requires minimal amounts of cell material and might even become applicable in vivo. We studied the dose-dependent aggregation of ASOs and the effect of different wing chemistries (locked nucleic acid, 2′-methoxyethyl and 2′-Fluoro) and ASO lengths on the interactome. Finally, we demonstrate the detection of stress-induced, intracellular interactome changes (actinomycin D treatment) with an in situ variant of the approach, which uses a recombinant biotin ligase and does not require genetic manipulation of the target cell.
- 17 January 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (5) , 555-565
Open AccessProfiling the interactome of oligonucleotide drugs by proximity biotinylation
Drug-ID is a novel method applying proximity biotinylation to identify drug–protein interactions inside living cells. The covalent conjugation of a drug with a biotin ligase enables targeted biotinylation and identification of the drug-bound proteome. We established Drug-ID for two small-molecule drugs, JQ1 and SAHA, and applied it for RNaseH-recruiting antisense oligonucleotides (ASOs). Drug-ID profiles the drug–protein interactome de novo under native conditions, directly inside living cells and at pharmacologically effective drug concentrations. It requires minimal amounts of cell material and might even become applicable in vivo. We studied the dose-dependent aggregation of ASOs and the effect of different wing chemistries (locked nucleic acid, 2′-methoxyethyl and 2′-Fluoro) and ASO lengths on the interactome. Finally, we demonstrate the detection of stress-induced, intracellular interactome changes (actinomycin D treatment) with an in situ variant of the approach, which uses a recombinant biotin ligase and does not require genetic manipulation of the target cell.